Valo Tx Working to Develop Potential COVID-19 Vaccine

contractpharmaApril 28, 2020

Tag: Valo Tx , COVID-19 , vaccine , PeptiCRAd

Valo Therapeutics Ltd. (Valo Tx), is working to develop a potential novel COVID-19 vaccine with applications across future pandemics. Valo Tx will use its PeptiCRAd technology to coat an (undisclosed) adenovirus vaccine vector, engineered to express coronavirus associated spike proteins, with HLA-matched peptides optimized to further boost CD8+ T-cell immune responses.

Both components of the proposed vaccine have been tested individually.  Non-replicating adenoviruses have been through clinical safety-testing and adenoviral vectors in general have been used safely in thousands of people across a wide range of ages. It is much faster to manufacture the clinical grade peptides necessary for coating the adenovirus, than re-engineering and manufacturing a new virus, making this approach more flexible and enabling clinical testing to progress quickly in the event that a new coronavirus strain emerges.

Most vaccines focus on boosting the antibody B cells response, but a T-cell immune response is important given that the infection targets the respiratory tract. COVID-19 replicates particularly fast and it appears that, by the time neutralizing antibodies are produced, many cells in the lungs have already become infected and require cell-mediated clearance. Adenoviral vectors are particularly strong at inducing T-cell mediated immune responses, and it is hoped that the SARS-COV-2 spike proteins will be processed to induce both T-cell and antibody mediated immunity to COVID-19. Additionally coating the adenovirus with peptides specifically selected for driving CD-8+ T-cells is expected to further enhance the cell mediated immune response; with the added capacity to broaden the immune targets.

CPhI China 2020 To Be Postponed to Dec. 16-18th,

Register as Visitor to the 20th Edition of CPhI China!

Register as Visitor to CPhI China 2020!

Editor's Note:

En-CPhI.CN is a vertical B2B online trade platform serving the pharmaceutical industry,

for any copyright disputes involved in the articles,

please email: to motify or remove the content.